Literature DB >> 36266638

Axillary vein thrombosis 30 h after caesarean section: a case report and literature review.

Benshuo Cai1, Gang Li2.   

Abstract

BACKGROUND: Axillary vein thrombosis is a very rare disorder. However, a case of axillary vein thrombosis shortly after caesarean section has not been reported previously. We report a case of axillary vein thrombosis 30 h after caesarean section due to an unidentified aetiology. CASE: A 37-year-old multiparous woman developed swelling and pain of the forearm and hand 30 h after undergoing a caesarean section. Doppler ultrasonography revealed a 14.9 mm × 5.3 mm thrombosis in the left axillary vein although a prophylaxis of anticoagulation was administrated. After an adjusted-dose of low-molecular-weight heparin (LMWH) was administered, the patient recovered and was discharged.
CONCLUSION: Obstetricians should be fully aware of the possibility of upper extremity deep vein thrombosis (DVT) despite its rarity, especially after the surgery. Lying in the lateral decubitus position for long periods postoperatively should be avoided as much as possible.
© 2022. The Author(s).

Entities:  

Keywords:  Axillary vein thrombosis; Caesarean section; Case report; Deep vein thrombosis; Low-molecular-weight heparin

Mesh:

Substances:

Year:  2022        PMID: 36266638      PMCID: PMC9585748          DOI: 10.1186/s12884-022-05122-y

Source DB:  PubMed          Journal:  BMC Pregnancy Childbirth        ISSN: 1471-2393            Impact factor:   3.105


  30 in total

1.  Venous thromboembolism in pregnancy: 21-year trends.

Authors:  Paul D Stein; Russell D Hull; Fadi Kayali; Ronald E Olson; Andrew K Alshab; Frederick A Meyers; William A Ghali; Allen Silbergleit; Paul Gibson
Journal:  Am J Med       Date:  2004-07-15       Impact factor: 4.965

2.  Axillary vein thrombosis during pregnancy: a case report.

Authors:  I Ben-Shlomo; G Azogui; A Prober; C Cozacov; S Zohar
Journal:  Obstet Gynecol       Date:  1992-09       Impact factor: 7.661

3.  Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study.

Authors:  Torben Bjerregaard Larsen; Henrik Toft Sørensen; Mette Gislum; Søren Paaske Johnsen
Journal:  Thromb Res       Date:  2007-01-25       Impact factor: 3.944

4.  Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy.

Authors:  R B Gherman; T M Goodwin; B Leung; J D Byrne; R Hethumumi; M Montoro
Journal:  Obstet Gynecol       Date:  1999-11       Impact factor: 7.661

5.  The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes.

Authors:  G J Kovacevich; S A Gaich; J P Lavin; M P Hopkins; S S Crane; J Stewart; D Nelson; L M Lavin
Journal:  Am J Obstet Gynecol       Date:  2000-05       Impact factor: 8.661

6.  Thrombosis during pregnancy and the postpartum period.

Authors:  Andra H James; Victor F Tapson; Samuel Z Goldhaber
Journal:  Am J Obstet Gynecol       Date:  2005-07       Impact factor: 8.661

7.  Subclavian vein thrombosis: a continuing challenge.

Authors:  S L Hill; R E Berry
Journal:  Surgery       Date:  1990-07       Impact factor: 3.982

8.  Pulmonary embolism following thrombosis of the brachial vein after shoulder arthroscopy. A case report.

Authors:  A Hariri; G Nourissat; C Dumontier; L Doursounian
Journal:  Orthop Traumatol Surg Res       Date:  2009-07-02       Impact factor: 2.256

9.  Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3' UTR and factor V Leiden mutations.

Authors:  B M C McGowan; L A Kay; D J Perry
Journal:  Am J Hematol       Date:  2003-08       Impact factor: 10.047

Review 10.  Current perspective of venous thrombosis in the upper extremity.

Authors:  L E Flinterman; F J M Van Der Meer; F R Rosendaal; C J M Doggen
Journal:  J Thromb Haemost       Date:  2008-05-15       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.